- BioShanghai brings state-backed and global investors together to fund companies across the drug-development cycle
- The initiative comes as China’s biotech financing market rebounds and capital shifts toward clinically validated assets
Shanghai is building a full-cycle financing ecosystem for biotech, bringing state-backed investors and global private-equity firms together to support companies from early research through clinical development and potential exits.
The “BioShanghai Investment and Financing Ecosystem” was launched September 17 at the 2026 Zhangjiang Pharma Valley Conference and BioShanghai Week in Shanghai’s Pudong.
Participants include Shanghai Industrial Investment Co. (SIIC), Shanghai State-owned Capital Investment, Advent International, CBC Group, GL Ventures and HongShan, among other domestic and global investors.
Early-mover advantage
The initiative is backed by a growing network of funds. Shanghai Bio-Medicine Fund II, managed by SIIC Capital, completed a 1.5 billion yuan ($224 million) first close in July, targeting companies from investigational new drug (IND) filing through Phase II trials.
This a stage when development risks have begun to fall but commercial value remains uncertain.
Together with its earlier fund, an innovation and commercialization fund, an M&A fund and a Hong Kong-based biotech fund, SIIC Capital says it now covers a company’s financing cycle from early incubation and clinical development to late-stage funding, listing and M&A.
Shanghai State-owned Capital Investment is also providing capital further upstream.
As of August, its three major fund-of-funds had invested nearly 10 billion yuan in 36 biotech-focused funds, generating about six times that amount in total investment, according to the company.
From projects to an ecosystem
The initiative reflects an effort to move from investing in individual biotech projects to building an ecosystem around them.
That matters because drug development typically requires years of research and large amounts of capital, while conventional investment incentives can favor shorter-term returns.
The resulting mismatch has historically made some state-backed investors reluctant to take on early-stage biotech risk.
The new model combines the longer investment horizon of state capital with the sector expertise and investment discipline of commercial investors.
Capital returns to biotech
The push comes as China’s biotech financing market shows signs of recovery.
Data from medical-data provider PharmCube shows that healthcare companies in China raised 72.56 billion yuan in the first half of 2026, up 41.7% from a year earlier.
Funding for innovative drugs surged 268.8% to 4.64 billion yuan, while Shanghai ranked first nationally with 17.48 billion yuan in healthcare financing.
Chinese drugmakers are also generating growing interest overseas. License-out deals by Chinese innovative drug companies totaled about $110 billion in the first half, roughly 80% of the full-year 2025 figure.
Eight of the global top 10 licensing deals involved Chinese sellers, according to PharmCube.
A shift in capital allocation
The rebound is accompanied by a shift in capital allocation: financing is moving toward earlier stages, while larger checks increasingly favor companies with proven clinical progress and commercialization potential.
BioShanghai’s fund matrix is designed to match that shift by providing capital at different stages, from early incubation to clinical development and M&A.
For Shanghai, the test will be whether state-backed patient capital and market-based investment expertise can work together efficiently enough to turn a collection of funds into a functioning biotech financing ecosystem.
Header image credit: Myriam Zilles/Unsplash
